

# Pulmonary nodules, is there any pathogenesis evidence?

## Abstract

Theory and treatment of pulmonary nodules is under-investigated in the clinic. Diagnostic and therapeutic norm is waiting for updating. This editorial highlights the pathogenesis and treatment of pulmonary nodes is.

**Keywords:** pulmonary disease, fibrosis, mental disorder, pathogenesis, immunomodulation

Volume 9 Issue 1 - 2023

**Da Yong Lu, Hong Ying Wu**

School of Life Science, Shanghai University, China

**Correspondence:** Da Yong Lu, School of Life Sciences, Shanghai University, Shanghai 200444, PR China, Email ludayon@shu.edu.cn

**Received:** February 02, 2023 | **Published:** February 17, 2023

## Introduction

Theory and treatment of pulmonary nodules is under-investigated in the clinic. Diagnostic and therapeutic updating is waiting for new ideas and knowledge. In this editorial, pathogenesis and potential treatment for pulmonary nodes is highlighted.

## Aims

Evidence and knowledge about pulmonary nodules is neglected in the past.<sup>1</sup> Potential risk and impacts to human health by pulmonary nodules must be found and targeted as effective as possible. Before therapeutic study, pathogenesis and diagnosis of pulmonary nodes should be explored.<sup>1</sup> Several approaches had been proposed.<sup>1,2</sup> Different therapeutics had been proposed for this clinical evidence, especially surgery and drug treatments in early investigation.

## Pathologic associations

A variety of medical discipline and evidence are associated. It is proposed that this evidence is not 100% associated with malignancy.<sup>1</sup> Many other pathological pathways and evidence has been compared and evaluated Table 1.

**Table 1** Potential pathogenesis evidence for the causation<sup>3-16</sup>

Disease categories	Process & pathways
Infectious diseases	Cytopathic and genomic integration
Gut microbiota	Neoplasia and immune responses
Respiratory diseases	Lung tissue and functional changes
Mental health problems	Central nerve system disorders
Physics & chemical	DNA damage and adduct
Immunity	Humoral or cellular changes
Genetic factors	Somatic mutation or tissue tumorigenesis
Underlying diseases	Homeostasis and vascular

## Histological evidence

To further prove these pathogenesis, clinical evidence should be discovered and accumulated in tissues and organs. A number of clinical evidence was suggested at genetic, metabolism, therapeutic and nutrition levels after growing clinical study.<sup>17-21</sup> System comparisons and integration can help these discoveries. We may learn more about this mystery event in medicine and techniques in the future.

## Therapeutic potentiality

There are different types of clinical treatments for this event and phenomenon. It contains surgery<sup>2</sup> different categories of drugs.<sup>22-24</sup> herbal medicine.<sup>25-28</sup> and many others. This kind of medical and pharmaceutical study should not be overlooked from now.

## Conclusion

The real architectures of disease pathogenesis, diagnosis and therapeutics will be progressed in the future. Good therapeutic drugs and selection can be achieved in the clinic. According to biomedical significance and progress of pulmonary nodules, personalized medicine may be useful.<sup>29-30</sup>

## Acknowledgments

None.

## Conflicts of interest

The author declares that there are no conflicts of interest.

## References

- Lu DY, Wu HY. Pulmonary nodules, surgery or other medication. *Nurse Care Open Acces J.* 2023;9(1):1.
- Lu DY, Wu HY. Pulmonary nodules, surgical indication and procedure optimization. *OSP Journal of Surgery.* 2023;2(1):1-2.
- Lu DY, Che JY, Yarla NS, et al. Type 2 diabetes study, introduction and perspective. *The Open Diabetes Journal.* 2018;8:13-21.
- Lu DY, Zhu PP, Wu HY, et al. Human suicide risk and treatment study. *Cent Nerv Syst Agents Med Chem.* 2018;18(3):206-212.
- Lu DY, Wu HY, Xu B. Pathology study for human suicide. *Health and Primary Care.* 2021;5:1-4.
- Lu DY, Lu TR, Wu HY. Avian flu, pathogenesis and therapy. *Anti-Infective Agents.* 2012;10(2):124-129.
- Lu DY, Che JY, Wu HY, et al. Obesity, risks and managements. *Metabolomics.* 2018;8(1):155.
- Brestoff JJR, Artis D. Immune regulation of metabolic homeostasis in health and disease. *Cell.* 2015;161(1):146-160.
- Quarta C, Schneider R, Tschop MH. Epigenetic ON/OFF switches for obesity. *Cell.* 2016;164(3):341-342.
- Lu DY, Che JY, Lu TR, et al. Pathology and treatments of obesity. *Trends in Medicine.* 2018;8(5):157.
- Malaviya A, Paari KA, Malviya S, et al. Gut microbiota and cancer correlates. *Probiotic Res in Therapeutics.* 2021;4:1-27.

12. Lu DY, Lu Y. Covid-19 infection for metabolic abnormal human beings. *Nurse Care Open Access J.* 2022;8(2):72–73.
13. Lu DY, Che JY, Yarla NS, et al. Type 2 diabetes study, introduction and perspective. *The Open Diabetes Journal.* 2018;8:13–21.
14. Lu DY, Ding J. Sequencing the whole genome of infected human cells obtained from diseased patients—a proposed strategy for understanding and overcoming AIDS or other deadliest virus-infected diseases. *Med Hypotheses.* 2007;68(4):826–827.
15. Smith AE, Helenius A. How viruses enter animal cells. *Science.* 2004;304(5668):237–242.
16. Taha H, Morgan T, Das A, et al. Parenteral patent drug S/GSK 1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection. *Recent Pat Antiinfect Drug Discov.* 2013;8(3):213–218.
17. Isik A, Wysocki AP, Memis U, et al. Factors associated with the occurrence and healing of umbilical pilonidal sinus: a rare clinical entity. *Adv Skin Wound Care.* 2022;35(8):1–4.
18. Kavousi S, Akbarialiabad H, Jalli R. The predictive association between radiological findings and lung cancer development in patients exposed to sulfur mustard gas: 4 decades follow up of 719 victims. *BMC Pulm Med.* 2022;22(1):481.
19. Chandler LG, Liu TS, Buckanovich R, et al. The double edge sword of fibrosis in cancer. *Transl Res.* 2019;209:55–67.
20. Helyer LK, Varnic M, Le LW, et al. Obesity is a risk factor for developing post-operative lymphedema in breast cancer patients. *Breast J.* 2010;16(1):48–54.
21. Isik A, Soran A, Grasi A, et al. Lymphedema after sentinel lymph node biopsy: who is at risk? *Lymphat Res Biol.* 2022;20(2):160–163.
22. Lu DY, Lu TR, Chen EH, et al. Anticancer drug development, system updating and global participation. *Current Drug Therapy.* 2017;12(1):37–45.
23. Lu DY, Lu TR, Chen EH, et al. Keep up the pace of drug development evolution and expenditure. *Cancer Rep Rev.* 2018;2(5):165.
24. Lu DY, Lu TR. Anticancer drug development, challenge and dilemma. *Nurse Care Open Acces J.* 2020;7(3):72–75.
25. Lu DY, Lu TR, Yarla NS, et al. Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug. *Studies in Natural Products Chemistry.* 2020;66:91–115.
26. Lu DY, Lu TR. Herbal medicine in new era. *Hos Pal Med Int J.* 2019;3(4):125–130.
27. Agarwal N, Majee C, Chakraborty GS. Natural herbs as anticancer drugs. *Int J PharmTech Res.* 2012;4(3):1142–1153.
28. Pattannayak S. Plants in healthcare: past, present and future. *Explor Anim Med Res.* 2021;11(2):140–144.
29. Lu DY. Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics, UK. *Elsevier.* 2014.
30. Lu DY, Lu TR, Che JY, et al. Individualized cancer therapy, future approaches. *Curr Pharmacogenom Personalize Med.* 2018;16(2):156–163.